Skyrizi® Alternatives

Skyrizi, an interleukin inhibitor, is prescribed to alleviate inflammation associated with plaque psoriasis, psoriatic arthritis, or Crohn's disease in adults. The recommended dose is 150mg administered every 12 weeks as two subcutaneous injections of 75mg, which patients can learn to self-administer. The most frequently reported side effects are upper respiratory tract infections, headache, and fatigue.

Skyrizi is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, and Crohn’s Disease.

Dupixent is an injectable medication that is typically administered subcutaneously every other week to treat inflammatory conditions, such as asthma and eczema, among others. Injection site reactions and eye conditions are the most frequently reported side effects. The risk of infection is low with Dupixent, unlike other biologics.

Dupixent is FDA approved for the following indications: Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyposis, Eosinophilic Esophagitis, Prurigo Nodularis.